HK Stock MarketDetailed Quotes
02607 SH PHARMA
- 10.280
- +0.020+0.19%
Market Closed Sep 13 16:08 CST
38.08BMarket Cap8.47P/E (TTM)
10.480High10.220Low3.68MVolume10.240Open10.260Pre Close38.21MTurnover0.40%Turnover Ratio9.16P/E (Static)3.70BShares12.43952wk High0.50P/B9.45BFloat Cap9.73952wk Low0.44Dividend TTM919.07MShs Float24.699Historical High0.441Dividend LFY2.53%Amplitude2.124Historical Low10.373Avg Price100Lot Size4.29%Div YieldTTM4.29%Div Yield LFY
SH PHARMA Key Stats
All
YOY
| (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 5.14%139.41B | 5.93%70.15B | 12.21%260.3B | 13.11%197.51B | 18.70%132.59B | 16.39%66.23B | 7.49%231.98B | 8.47%174.61B | 6.15%111.71B | 10.27%56.9B |
| Operating income | 5.14%139.41B | 5.93%70.15B | 12.21%260.3B | 13.11%197.51B | 18.70%132.59B | 16.39%66.23B | 7.49%231.98B | 8.47%174.61B | 6.15%111.71B | 10.27%56.9B |
| Operating expenses | -6.67%-123.25B | -7.87%-62.12B | -13.63%-228.97B | -14.22%-173.55B | -19.50%-115.53B | -16.19%-57.59B | -7.59%-201.49B | -9.10%-151.93B | -5.98%-96.68B | -11.02%-49.57B |
| Gross profit | -5.22%16.17B | -7.03%8.03B | 2.76%31.33B | 5.67%23.96B | 13.51%17.06B | 17.80%8.63B | 6.81%30.49B | 4.45%22.68B | 7.26%15.03B | 5.41%7.33B |
| Selling expenses | 15.10%-6.57B | 15.86%-3.29B | 2.64%-13.9B | -1.29%-10.47B | -13.81%-7.73B | -18.05%-3.91B | -7.22%-14.28B | -1.18%-10.34B | -7.42%-6.79B | -4.23%-3.31B |
| Administrative expenses | -3.86%-2.87B | -0.90%-1.39B | -14.43%-5.71B | -11.62%-4.19B | -19.00%-2.76B | -15.70%-1.38B | 2.95%-4.99B | -5.09%-3.76B | 0.03%-2.32B | 2.57%-1.19B |
| Research and development expenses | -7.67%-1.11B | 7.26%-501.45M | -4.35%-2.2B | -5.70%-1.47B | -26.76%-1.03B | -20.82%-540.69M | -6.29%-2.11B | -1.63%-1.39B | 7.99%-809.67M | -7.95%-447.5M |
| Profit from asset sales | 88.91%139.31M | 405.21%110.04M | -93.57%92.48M | -92.67%104.58M | -94.83%73.75M | 188.72%21.78M | 2,368.58%1.44B | 22,234.19%1.43B | 23,988.34%1.43B | 7,912.76%7.54M |
| Revaluation surplus | -41.94%114.29M | -41.55%52.25M | 85.03%404.73M | 225.04%239.02M | 675.23%196.84M | 240.65%89.4M | 206.18%218.74M | 141.65%73.54M | 171.34%25.39M | 47.56%-63.56M |
| -Changes in the fair value of other assets | -41.94%114.29M | -41.55%52.25M | 85.03%404.73M | 225.04%239.02M | 675.23%196.84M | 240.65%89.4M | 206.18%218.74M | 141.65%73.54M | 171.34%25.39M | 47.56%-63.56M |
| Impairment and provision | -22.04%-329.78M | -42.34%-241.8M | -30.64%-841.24M | -15.91%-262.6M | -51.60%-270.22M | -362.28%-169.87M | -360.73%-643.93M | 13.13%-226.55M | 3.90%-178.24M | 60.88%-36.75M |
| -Other impairment is provision | -22.04%-329.78M | -42.34%-241.8M | -30.64%-841.24M | -15.91%-262.6M | -51.60%-270.22M | -362.28%-169.87M | -360.73%-643.93M | 13.13%-226.55M | 3.90%-178.24M | 60.88%-36.75M |
| Special items of operating profit | 124.15%384.1M | -34.56%233.27M | -21.78%725.04M | -49.72%346.45M | -61.50%171.36M | 41.47%356.49M | -59.88%926.88M | -67.03%689.04M | -76.12%445.11M | -83.73%251.99M |
| Operating profit | 3.86%5.54B | -4.11%2.79B | -11.38%9.15B | -10.54%7.71B | -17.32%5.33B | 23.59%2.91B | 9.28%10.33B | 11.48%8.62B | 11.00%6.45B | -28.85%2.35B |
| Financing cost | 8.70%-705.94M | 10.46%-374.43M | -13.14%-1.49B | -15.71%-1.15B | -19.16%-773.22M | -16.64%-418.18M | -5.45%-1.31B | -7.26%-997.59M | -12.10%-648.91M | -13.43%-358.53M |
| Special items of earning before tax | 63.46%-8.88M | 54.93%2.02M | -197.11%-612.94M | 30.84%-36.96M | 41.10%-24.29M | 115.24%1.3M | -234.51%-206.3M | -1,031.28%-53.44M | -228.25%-41.24M | -261.75%-8.55M |
| Earning before tax | 6.36%4.82B | -3.02%2.42B | -19.91%7.05B | -13.86%6.52B | -21.26%4.53B | 25.44%2.49B | 8.16%8.81B | 11.35%7.57B | 10.36%5.76B | -33.72%1.99B |
| Tax | -9.66%-1.22B | -2.28%-551.13M | -3.93%-1.89B | 1.16%-1.57B | 6.45%-1.12B | -18.63%-538.85M | 2.83%-1.82B | -10.54%-1.58B | -13.39%-1.19B | 26.63%-454.25M |
| After-tax profit from continuing operations | 5.28%3.6B | -4.48%1.87B | -26.11%5.17B | -17.22%4.95B | -25.14%3.42B | 27.46%1.95B | 11.43%6.99B | 11.56%5.98B | 9.59%4.56B | -35.56%1.53B |
| Earning after tax | 5.28%3.6B | -4.48%1.87B | -26.11%5.17B | -17.22%4.95B | -25.14%3.42B | 27.46%1.95B | 11.43%6.99B | 11.56%5.98B | 9.59%4.56B | -35.56%1.53B |
| Minority profit | -18.80%655.45M | -25.75%323.29M | 1.72%1.4B | -1.14%1.16B | -7.07%807.18M | 54.77%435.4M | 16.41%1.37B | 33.04%1.17B | 45.49%868.61M | 9.10%281.31M |
| Profit attributable to shareholders | 12.72%2.94B | 1.62%1.54B | -32.92%3.77B | -21.13%3.8B | -29.38%2.61B | 21.31%1.52B | 10.28%5.62B | 7.35%4.81B | 3.58%3.7B | -40.99%1.25B |
| Basic earnings per share | 11.27%0.79 | 2.44%0.42 | -36.65%1.02 | -28.97%1.03 | -37.17%0.71 | -6.82%0.41 | -10.06%1.61 | -8.23%1.45 | -10.32%1.13 | -41.33%0.44 |
| Diluted earnings per share | 11.27%0.79 | 2.44%0.42 | -36.65%1.02 | -28.97%1.03 | -37.17%0.71 | -6.82%0.41 | -10.06%1.61 | -8.23%1.45 | -10.32%1.13 | -41.33%0.44 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
| Auditor | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data